NASDAQ$CLPT
ClearPoint Neuro Inc · Q4 2019 earnings
Q4 2019 earnings · · Investor relations
Briefing
Reported a 41% increase in fourth quarter revenue, marking the fifth consecutive quarter of revenue growth.
ClearPoint Neuro reported a 53% increase in revenue for the full year 2019, with fourth-quarter revenue growing by 41%. The company saw growth across all four segments of its business and secured over $25 million in financing from strategic partners.
- Total revenues increased by 53% year-over-year for 2019.
- Functional neurosurgery revenue increased by 29% for 2019, driven by a 20% increase in cases utilizing the ClearPoint Neuro Navigation System.
- Biologics and drug delivery revenue increased by 116% for 2019, due to growth in clinical services and product sales.
- Capital equipment sales and related service revenue increased for 2019, primarily due to an increase in sales of ClearPoint systems.
Headline financials
Revenue & EPS history
ClearPoint Neuro · Revenue · Quarterly
$3.21M
Revenue by segment
ClearPoint Neuro · $1.55M total across 2 segments · Q4 2019
- Biologics and Drug Delivery$1.1M+103.7%71.2%
- Capital Equipment and Software$446K—28.8%
Forward guidance
The company expects to submit or introduce several new products in 2020 and believes new biologics and gene therapy partnerships will lead to exciting new applications.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q4 2019
-1.7%
Avg return
Earnings day
-1.7%
Avg return
5 days after
-2.3%
Avg return
30 days after
34%
15 / 44 earnings
Positive
+35.8%
Q2 2024
Best reaction
-24.1%
Q3 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -3.9% | -12.1% | +6.9% | |
| Q4 2025 | -14.5% | -14.8% | +5.6% | |
| Q3 2025 | -13.5% | -8.3% | -25.7% | |
| Q1 2025 | -11.7% | -7.6% | -18.7% | |
| Q4 2024 | -17.5% | -22.1% | -30.5% | |
| Q3 2024 | -12.9% | -16.9% | +0.7% | |
| Q2 2024 | +35.8% | +46.6% | +78.3% | |
| Q1 2024 | +0.8% | -1.3% | -3.4% | |
| Q4 2023 | +18.9% | +18.6% | +2.8% | |
| Q3 2023 | -24.1% | -14.3% | +13.9% | |
| Q2 2023 | -5.0% | -8.9% | -20.2% | |
| Q1 2023 | -7.0% | -8.8% | -28.2% | |
| Q4 2022 | -3.3% | -4.5% | -0.5% | |
| Q3 2022 | -3.5% | +2.6% | -6.9% | |
| Q2 2022 | +10.3% | +9.6% | -14.3% | |
| Q1 2022 | +1.0% | +17.0% | +49.0% | |
| Q4 2021 | -0.1% | +6.2% | +19.0% | |
| Q3 2021 | -8.3% | -11.3% | -35.1% | |
| Q2 2021 | -17.6% | -20.2% | -13.2% | |
| Q1 2021 | +3.2% | +4.5% | +15.7% | |
| Q4 2020 | -22.8% | -14.0% | -3.9% | |
| Q3 2020 | +13.3% | +25.3% | +52.9% | |
| Q2 2020 | -2.2% | +5.3% | +12.2% | |
| Q1 2020 | -12.4% | -14.9% | +7.2% | |
| Q4 2019 | +18.8% | +13.6% | -16.3% | |
| Q3 2019 | -0.7% | +2.3% | +5.4% | |
| Q2 2019 | +5.8% | -1.2% | -1.0% | |
| Q1 2019 | +7.4% | +10.6% | +16.2% | |
| Q4 2018 | -3.1% | -3.1% | -8.3% | |
| Q3 2018 | -2.4% | -4.9% | -14.6% | |
| Q2 2018 | -2.2% | -6.6% | -20.9% | |
| Q1 2018 | -5.6% | -7.4% | -22.6% | |
| Q3 2017 | +1.5% | -8.0% | -0.4% | |
| Q2 2017 | -0.5% | +8.4% | +1.1% | |
| Q1 2017 | +0.0% | -3.9% | -43.0% | |
| Q3 2016 | +17.9% | -3.8% | -23.1% | |
| Q2 2016 | -5.9% | -15.3% | -20.7% | |
| Q2 2015 | -11.3% | — | — | |
| Q1 2015 | -5.6% | — | — | |
| Q2 2014 | +0.0% | — | — | |
| Q1 2014 | +2.4% | — | — | |
| Q2 2012 | +1.7% | — | — | |
| Q1 2013 | -0.8% | — | — | |
| Q3 2012 | +3.3% | — | — | |
| Q1 2012 | — | — | — | |
| Q4 2011 | — | — | — | |
| Q3 2011 | — | — | — | |
| Q2 2011 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro